I think Apotex is a leader in Canada. It took the opportunity, the challenge, and went forward. I would say that there was tremendous enthusiasm within that company. People worked long hours, they worked weekends and evenings to try to get the product approved as quickly as possible. There was a great sense that they were doing something important when they did it.
When I talked to the Apotex executives...I think they found that the whole process was very lengthy, uncertain, and led to too-small shipments. The process would have to be started again. Apotex and other companies are able to provide good prices and volume products by being large-volume producers. They don't specialize in little shipments, buying a product or making a small amount and selling it. That's not the way to get good prices. That's not the way to develop economies of scale. If they've identified a product and work as they did in the past with Doctors Without Borders and with Health Canada, and see a need for a product that they've developed, they'd like to be able to produce that in large quantities, subject to the rules, but then sell it with some certainty. They don't have that, and that's really, I think, in large measure why they found this process unsatisfactory.